3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Melanoma
10
Multiple Myeloma
7
Glioma
6
Neoplasm Metastasis
5
Lymphoma
5
Hematologic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Neurofibromatosis 1
4
Pancreatic Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Thyroid Neoplasms
2
Neurofibroma, Plexiform
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Juvenile
2
Glioblastoma
2
Brain Neoplasms
2
Astrocytoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
trametinib
×
90 days
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled